Applied Molecular Transport Inc (AMTI) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of oral biologic therapies for patients with serious diseases. The company's proprietary technology platform is designed to enable the oral delivery of biologics, which are currently administered through injections.
Here are some key financial highlights for AMTI based on its latest financial statements:
As of September 30, 2021, AMTI reported total assets of $125.8 million and total liabilities of $19.4 million.
The company reported a net loss of $17.1 million for the nine months ended September 30, 2021, compared to a net loss of $10.2 million for the same period in 2020.
AMTI reported no revenue for the nine months ended September 30, 2021, compared to $3.3 million in revenue for the same period in 2020.
As of September 30, 2021, the company had cash, cash equivalents, and marketable securities of $108.6 million, which it believes will be sufficient to fund its operations into 2023.
Overall, AMTI is a clinical-stage biopharmaceutical company that is focused on developing and commercializing oral biologic therapies. The company has reported losses in recent periods, as it invests in research and development activities. However, the company has a strong balance sheet with significant cash reserves, which should allow it to continue its operations for the foreseeable future.
|
